Company intelligence / Profile preview

Cannasat Therapeutics Inc.

Toronto, Ontario, Canada

Ownership: Private
Development stage: Other

Overview

Developed APL-130277, a sublingual thin film formulation of apomorphine for on-demand treatment of OFF episodes in Parkinson's disease. Completed Phase 2 and initiated Phase 3 clinical program using 505(b)(2) pathway, with NDA planned for late 2016 or early 2017.[3]

Therapeutic areas: Neurology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Cannasat Therapeutics Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cannasat Therapeutics Inc..

Explore the full profile